CCL2 and cancer: Numerous studies have shown that cytokines are pivotal drivers of disease progression in cancer patients, leading to the development of innovative therapeutic strategies that block cytokine‐related signaling pathways.[77, 78, 79, 80, 81, 82] In this study, we explored three powerful approaches to disrupt the reciprocal signaling loop between cancer cells and ADSCs in coculture: 1) silencing HIF‐1α and CCL2 in cancer cells, 2) silencing CCR2 and PPARα in ADSCs, 3) treatment with nAb‐CCL2.